NEW YORK (Reuters) – Many of the most important pharmacies and drug dealers in the United States do not have the generic version of the EpiPen lifeline allergy treatment of Teva Pharmaceutical Industries Ltd five months after the sale in the United States was approved, the drug chains and a group that tracks the shortage of drugs to Reuters.
DATA SHEET: EpiPen's self-injectable epinephrine pens manufactured by the pharmaceutical company Mylan NV for use by serious allergy sufferers appear in Washington, United States on August 24, 2016. REUTERS / Jim Bourg / Photo Archive
Shortage represents a missed opportunity for Teva to compete with Mylan NV in a $ 750 million market a year. Mylan's EpiPen dominates that market, but it was soon since May, leaving many patients and their families interested in alternatives.
"The generic version of EpiPen Auto-Injector is currently available and we continue to build the offer," said Teva in an email statement. "We are actively manufacturing and shipping products throughout the country."
The company did not say why its drug was scarce.
Teva, the largest generic producer in the world, received approval from the United States for its version of EpiPen in August after several years of delay. At that time, the company pledged its "full resources for this important release in the coming months."
The Food and Drug Administration of the USA UU. He claimed the product as a lower cost option for patients who depend on access to EpiPen and similar portable devices that facilitate administration of epinephrine in the event of a severe allergic reaction, such as bee stings or peanut exposure.
Mylan's EpiPen is soon due to manufacturing problems in the single Pfizer Inc plant that makes the auto-injectors.
"We continue to receive interrupted phone calls from parents because they can not receive epinephrine for their children," said Kim Mudd, head of the Johns Hopkins University pediatric allergy unit's nurse.
At the end of November, Teva said her generic EpiPen for adults was available in limited supply in the United States and promised that more of the product, as well as a version for children, would be available in 2019. Reuters checks at the end of January suggest That even the available offer decreased.
"We received pharmacy reports and we could confirm with suppliers that they are in order," said Erin Fox, a professor at the University of Utah.
Fox maintains a list of independent drug shortages for the American Association of Health System Pharmacists (ASHP) and added the Teva version of EpiPen to the list this week. The device also appears in the FDA drug list in the shortage.
CVS Health Corp said it received limited supplies from the Teva device at the end of last year, but it currently does not have it in stock. Walmart Inc is not taking EpiPen from Teva at its pharmacies, according to a source familiar with the matter.
Fox said pharmacies can not yet order the devices through major distributors Cardinal Health Inc or AmerisourceBergen Corp. A spokeswoman for AmerisourceBergen refused to comment and Cardinal Health did not immediately respond to a comment request.
Walgreens said that it currently has a limited supply of certain generic epinephrine products, including Teva's, in some of its pharmacies. Cigna Corp's Scripts Express unit said it has a limited supply of Teva devices at its home delivery pharmacy.
Wall Street saw EpiPen's rival a benefit benefit for Teva, since it maintains the sharp decline in US margins for its older generic medications and a series of expensive acquisitions. The pharmacist shot thousands of employees and worked to reduce their debt.
When the approval of the device was announced last year, shares in the United States' list of Teva rose 6%. Wall Street analysts suggested it could add $ 250 million to Teva's revenues annually and represent an increase of 4 cents at 6 cents per share in profits.
Analysts, on average, expect the company to publish revenues of $ 2.80 per share in 2019, according to data from Refinitiv's IBES.
Teva's devices accounted for only 3 percent of the EpiPen market for the week of January 18, according to a research note from Leerink citing IQVIA data on the volume of prescription. This fell from 7 percent a month earlier and is compared to approximately 64 percent of market share that Mylan has branded and authorizes generic EpiPens.
Lisa Gable, the executive director of the patient's Food Allergy Research & Education patient group, hoped Teva's approval helped alleviate the shortage of EpiPen devices, especially as families seek to renew their prescriptions before the summer or new summer camp. school year
"The community has been affected by shortages because of a relatively small supplier base," Gable said.
Presentation of reports by Michael Erman and Jilian Mincer; editing by Michele Gershberg, Bill Rigby and Bill Berkrot